HRT Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

HRT Financial’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,069	Closed	-$1.03M	–	3372
2023 Q2	$1.03M	Buy	10,069 +7,376	+274%	+$698K	0.01%	935
2023 Q1	$244K	Sell	2,693 -26,589	-91%	-$1.56M	﹤0.01%	1835
2022 Q4	$1.11M	Sell	29,282 -11,035	-27%	-$380K	0.02%	895
2022 Q3	$1.01M	Buy	+40,317	New	+$1.12M	0.01%	896
2021 Q2	–	Sell	-4,961	Closed	-$494K	–	3722
2021 Q1	$494K	Buy	+4,961	New	+$579K	0.01%	1796
2020 Q4	–	Sell	-12,767	Closed	-$1.24M	–	2646
2020 Q3	$1.24M	Buy	12,767 +5,668	+80%	+$708K	0.04%	410
2020 Q2	$1.11M	Buy	7,099 +5,308	+296%	+$807K	0.03%	516
2020 Q1	$258K	Buy	+1,791	New	+$346K	0.02%	527

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HRT Financial's RETA Position: Q3 2023 in Review

HRT Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 10,069 shares — an estimated $1.03M sold.

HRT Financial first reported a position in RETA in Q1 2020 and held it in 8 quarters. The position peaked at $1.24M in Q3 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

HRT Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
HRT Financial sold 10,069 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.03M.
HRT Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 8 quarters.
HRT Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.24M in Q3 2020.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on HRT Financial's 13F filing for Q3 2023, filed 13 Nov 2023.